Our Corporate Culture
We are convinced that iTeos’ values are key to our success. Our single greatest asset is our people; their science, collective expertise, commitment and dedication is the foundation to iTeos’ and its goal of bringing new, curative treatments to patients.
iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing next generation immunotherapies. The Company advanced EOS100850, an insurmountable and non-brain penetrant adenosine A2A receptor antagonist, into a Phase I trial in the February 2019. A second program for its human ADCC-enabling anti-TIGIT antibody (EOS884448) is expected to enter the clinic in the second half of 2019. Based in Gosselies, Belgium and Cambridge, MA, iTeos Therapeutics was founded out of the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (Université Catholique de Louvain) in 2011. In June 2018, the Company completed a $75 million (€64 million) Series B financing led by MPM Capital, alongside new investors HBM Partners, 6 Dimensions Capital and Curative Ventures. All previous investors including Fund +, VIVES II and SRIW, as well as SFPI, also participated in this funding round.
iTeos Therapeutics has the ambition of becoming a world-class leader in the sector and is continually looking to bring life science entrepreneurs and creative scientists to iTeos to supplement our expertise and help deliver new medicines to patients. iTeos is growing significantly at this time and if you are excited about our vision and values, send your resume to email@example.com and tell us how you can contribute to the success of iTeos Therapeutics.